Kristijan Skok

Dr. Kristijan Skok

Institute of Pathology, Medical University of Graz, Graz, Steiermark, Austria
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
SLSigurd F. Lax
Sigurd F. Lax
Kristijan SkokKristijan Skok
Kristijan Skok
PZPeter Zechner
Peter Zechner
HKHarald H. Kessler
Harald H. Kessler
NKNorbert Kaufmann
Norbert Kaufmann
MTMichael Trauner
Michael Trauner
The clinicopathological basis for morbidity and mortality with SARS-CoV-2 infection is not well understood. This study reports the clinical and autopsy findings of patients who died of COVID-19. Background: Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become pandemic, with substantial mortality. Objective: ...

10 March 2022 in Physics of Life Reviews
Verified
Journal Article
Open access
Marko GosakMarko Gosak
Marko Gosak
MMMarko Milojević
Marko Milojević
MDMaja Duh
Maja Duh
Kristijan SkokKristijan Skok
Kristijan Skok
Matjaz PercMatjaz Perc
Matjaz Perc
Technological advances in imaging techniques and biometric data acquisition have enabled us to apply methods of network science to study the morphology and structural design of organelles, organs, and tissues, as well as the coordinated interactions among them that yield a healthy physiology at the level of whole organisms. We here review research dedicated to these advances, in particular focusing on networks between cells, the topology of multicellular structures, neural interactions, fluid transportation networks, and anatomical networks. The percolation of blood vessels, structural connectivity within the brain, the porous structure of bones, and relations between different anatomical parts of the human body are just some of the examples that we explore in detail. We argue and show that the models, methods, and algorithms developed in the realm of network science are ushering in a new era of network-based inquiry into the morphology and structural design of living systems in the broadest possible terms. We also emphasize that the need and applicability of this research is likely to increase significantly in the years to come due to the rapid progress made in the development of bioartificial substitutes and tissue engineering.

15 August 2019 in Medicina
Verified
Journal Article
Open access
PDF file
Kristijan SkokKristijan Skok
Kristijan Skok
GHGaja Hladnik
Gaja Hladnik
AGAnja Grm
Anja Grm
ACAnton Crnjac
Anton Crnjac
Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease. It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent. Additionally, the process of pathogenesis is greatly affected by activating mutations of EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK and RET, which correlate with an increased incidence of MPE. Considering all these changes, the authors aim to present a literature review of the newest findings, review of the guidelines and pathophysiological novelties in this field. Review of the just recently, after seven years published, practice guidelines, as well as analysis of more than 70 articles from the Pubmed, Medline databases that were almost exclusively published in indexed journals in the last few years, have relevance and contribute to the better understanding of the presented topic. MPE still presents a severe medical condition in patients with advanced malignancy. Recent findings in the field of pathophysiological mechanisms of MPE emphasize the role of molecular factors and mutations in the dynamics of the disease and its prognosis. Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. The current guidelines address multiple areas of interest bring novelties in the form of validated prediction tools and can, based on evidence, improve patient outcomes. However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.

1 January 2017 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
KOKristjan Orthaber
Kristjan Orthaber
MPMatevž Pristovnik
Matevž Pristovnik
Kristijan SkokKristijan Skok
Kristijan Skok
BPBarbara Perić
Barbara Perić
Uroš MaverUroš Maver
Uroš Maver
The life expectancy in the Western world is increasing for a long time, which is the courtesy of a higher life standard, a more thorough hygiene, and, of course, the progress of modern medicine. Nevertheless, one of the illnesses that still proves to be a great challenge regardless of the recent advancements in medicine is cancer. Skin cancer is, according to the World Health Organization, the most common malignancy for the white population. The beginning of the paper offers a brief overview of the latest available information concerning epidemiology, aetiology, diagnostics, and treatment options for skin cancer, whereas the rest of the article deals with modern approaches to skin cancer treatment, highlighting recent development of nanotechnology based treatment approaches. Among these, we focus especially on the newest nanotechnological approaches combined with chemotherapy, a field which specialises in target specificity, drug release control, and real time monitoring with the goal being to diminish unwanted side effects and their severity, achieving a cheaper treatment and a generally more efficient chemotherapy. The field of nanotechnology is a rapidly developing one, judging by already approved clinical studies or by new theranostic agents that combine both the therapeutic and diagnostic modalities.

20 August 2020 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
Kristijan SkokKristijan Skok
Kristijan Skok
ESEvelyn Stelzl
Evelyn Stelzl
MTMichael Trauner
Michael Trauner
HKHarald H. Kessler
Harald H. Kessler
SLSigurd F. Lax
Sigurd F. Lax
The persistence of SARS-CoV-2 after death of infected individuals is unclear. The aim of this study was to investigate the presence of SARS-CoV-2 RNA in different organs in correlation with tissue damage and post-mortem viral dynamics in COVID-19 deceased. Twenty-eight patients (17 males, 11 females; age 66–96 years; mean 82.9, median 82.5 years) diagnosed with COVID-19 were studied. Swabs were taken post-mortem during autopsy (N = 19) from the throat, both lungs, intestine, gallbladder, and brain or without autopsy (N = 9) only from the throat. Selective amplification of target nucleic acid from the samples was achieved by using primers for ORF1a/b non-structural region and the structural protein envelope E-gene of the virus. The results of 125 post-mortem and 47 ante-mortem swabs were presented as cycle threshold (Ct) values and categorized as strong, moderate, and weak. Viral RNA was detected more frequently in the lungs and throat than in the intestine. Blood, bile, and the brain were negative. Consecutive throat swabs were positive up to 128 h after death without significant increase of Ct values. All lungs showed diffuse alveolar damage, thrombosis, and infarction and less frequently bronchopneumonia irrespective of Ct values. In 30% the intestine revealed focal ischemic changes. Nucleocapsid protein of SARS-CoV-2 was detected by immunohistochemistry in bronchial and intestinal epithelium, bronchial glands, and pneumocytes. In conclusion, viral RNA is still present several days after death, most frequently in the respiratory tract and associated with severe and fatal organ damage. Potential infectivity cannot be ruled out post-mortem.

8 April 2025 in Cancer Letters
Verified
Journal Article
Open access
KBKonstantin Bräutigam
Konstantin Bräutigam
Kristijan SkokKristijan Skok
Kristijan Skok
KSKrzysztof Szymoński
Krzysztof Szymoński
CRCharlotte Vestrup Rift
Charlotte Vestrup Rift
EKEva Karamitopoulou
Eva Karamitopoulou
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most deadly malignancies with a highly immunosuppressive tumor immune microenvironment (TIME) that hinders effective therapy. PDAC is characterized by significant heterogeneity in immune cell composition, spatial distribution and activation states, which impacts tumor progression and treatment response. Tumour-infiltrating lymphocytes (TILs), including CD4+ T-helper cells, CD8+ cytotoxic T-cells and FOXP3+ regulatory T-cells, play a key role in immune regulation, yet PDAC is largely an immunologically "cold" tumour with limited effector T-cell infiltration. The surrounding cellular microenvironment, particularly Cancer Associated Fibroblasts (CAFs) and macrophages, contributes to immune evasion by promoting a fibrotic and desmoplastic barrier that limits TIL infiltration. The prognostic significance of TILs is increasingly recognized, with higher densities correlating with improved survival, whereas regulatory T-cell infiltration and immunosuppressive stromal interactions are associated with poor outcomes. Emerging therapeutic strategies targeting the TIME (e.g., CAFs), immune checkpoint inhibitors, and TIL-based therapies offer the potential to overcome resistance. Future research must focus on optimizing immunotherapy strategies and unravelling the complex stromal-immune interactions to improve clinical translation.